Skip to Content

Posts tagged with "Drug Assays"

  • Drug Assays

    The End of Compound Property Optimization Is At Hand

    Here’s another Big Retrospective Review of drug pipeline attrition. This sort of effort goes back to the now-famous Rule-of-Five work, and readers will recall the Pfizer roundup of a few years back, followed by an AstraZeneca one (which didn’t always recapitulate the Pfizer pfindings, either). This latest is a joint effort to look at th… Read More
  • Animal Testing

    Organ Models on Chips

    Why do we test new drug candidates on animals? The simple answer is that there’s nothing else like an animal. There are clearly chemical and biological features of living systems that we don’t yet understand, or even realize exist – the discovery of things like siRNAs is enough proof of that. So you’re not going… Read More
  • Drug Assays

    Target (In)validation

    Here’s a short review in ACS Medicinal Chemistry Letters on target validation. As the author (Ramzi Sweis of AbbVie) says, it’s easy for medicinal chemists to lose track of that being part of their role: Too often, medicinal chemistry teams blindly accept the biological underpinnings of a new program as sound and are unaware that… Read More
  • Biological News

    Crappy Antibodies: Available Now, and for the Foreseeable Future

    I made a brief mention of this article yesterday, but I wanted to highlight it. It’s a look, from Nature News, at the broader implications of the antibody problem in research. Antibodies are, of course, universal reagents in molecular biology assays. If you suddenly declared their use illegal, the field would just collapse. But we… Read More
  • Aging and Lifespan

    A Young Blood Controversy

    The recent revival of interest in the way that the blood from younger animals (and people?) can improve the health of older ones came bundled with a particular protein candidate for the effect, GDF11. Several papers appeared on its effects in vivo, but there were people who found that odd, according to Nature News. Those… Read More
  • Analytical Chemistry

    Fun With Thermodynamics

    Here’s a very good review in J. Med. Chem. on thermodynamics and drug discovery. That topic has come up at this site several times over the years, and I’ve been wondering if anyone’s reached a consensus yet. What I take away from this new article is “Nope. Not yet.” Update: see also this review, also… Read More
  • Drug Assays

    More on TC-2153

    Yesterday’s post on TC-2153 and its assay activity brought a note from Paul Lombroso at Yale, whose group is doing this work. With his permission, here’s an update (slightly edited): We have now used the drug orally in nonhuman primates with cognitive deficits: it had significant results. . .we have also given it to both… Read More
  • Alzheimer's Disease

    Sulfur, Sulfur, Sulfur

    Does anyone know of any phosphatase inhibitors that aren’t hideous? I ask this because someone sent along a question about this paper, from last August, that I’d missed at the time (press release here, but the paper’s open-access as well). Here’s a commentary in the journal itself. It’s work from Yale on an enzyme call… Read More
  • Drug Assays

    Colorful Compounds Strike Again

    Here’s a paper of the sort that I wish more people would publish: a report of a false positive compound, and why it was a false positive. The authors, from the Helmholtz Institute at Saarland University, were screening for compounds that might directly inhibit bacterial RNA polymerase. That’s certainly a worthwhile target, although (lik… Read More
  • Drug Assays

    Silicon Valley Sunglasses

    The intersection between Silicon-Valley-style tech and biotech is getting a lot of attention these days. Some of it looks like it could be a productive synthesis: 23andMe hiring Richard Scheller of Genentech (update: and Robert Gentleman, today) as it starts its own efforts in drug discovery and Google bringing on Art Levinson (Genentech’s fo… Read More